Disease Progression in DLBCL: Management Strategies and Quality-of-Life Considerations

Experts discuss how disease progression impacts patients with diffuse large B-cell lymphoma (DLBCL) and strategies for managing progressive disease based on first-line therapy selection, incorporating insights from the POLARIX 5-year subsequent treatment data and highlighting quality-of-life considerations that influence treatment decisions.

EP: 1.Advances in DLBCL Management: Long-Term Treatment Outcomes

EP: 2.Long-Term Outcomes and Treatment Guidelines in DLBCL Management

EP: 3.Evolving Treatment Strategies in DLBCL: Real-World Clinical Experience

EP: 4.DLBCL Subtype Response Patterns: Optimizing Treatment Selection

Now Viewing

EP: 5.Disease Progression in DLBCL: Management Strategies and Quality-of-Life Considerations

EP: 6.Treatment Decision-Making in DLBCL: Balancing Efficacy, Safety, and Patient Factors

EP: 7.Long-Term Data and Future Directions in First-Line DLBCL Treatment

Video content above is prompted by the following:

Please describe how disease progression impacts patients with DLBCL and the approaches to managing progressive disease based on first-line therapy selection.
• How do the POLARIX 5-year subsequent treatment data inform your approach, and what quality-of-life considerations influence your treatment approach?

Recent Videos